Catalyst gives positive hemophilia update as 2 more subjects complete study

Two additional subjects completed Catalyst Biosciences' ongoing hemophilia Phase 2/3 trial without any bleeding or developing any anti-drug antibodies (ADAs), the company said in a statement Wednesday.